Literature DB >> 17725705

Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?

R W Bilous.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17725705     DOI： 10.1111/j.1464-5491.2007.02259.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN： 0742-3071            Impact factor:   4.359


× No keyword cloud information.
  2 in total

1.  PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?

Authors:  Siripong Palee; Siriporn Chattipakorn; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  World J Cardiol       Date:  2011-05-26

2.  Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.

Authors:  Zeina A Habib; Leonidas Tzogias; Suzanne L Havstad; Karen Wells; George Divine; David E Lanfear; Jeffrey Tang; Richard Krajenta; Manel Pladevall; L Keoki Williams
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-06       Impact factor: 2.890
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.